Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
4
-
Total 13F shares, excl. options
-
326K
-
Shares change
-
+190K
-
Total reported value, excl. options
-
$19.7M
-
Value change
-
+$11.6M
-
Number of buys
-
3
-
Number of sells
-
-2
-
Price
-
$59.86
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q4 2023
5 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q4 2023.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 4 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 326K shares
of 125M outstanding shares and own 0.26% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (16.4M shares), EcoR1 Capital, LLC (11.2M shares), Avoro Capital Advisors LLC (11.1M shares), VANGUARD GROUP INC (9.56M shares), T. Rowe Price Investment Management, Inc. (6.3M shares), BlackRock Inc. (5.38M shares), JENNISON ASSOCIATES LLC (3.28M shares), MORGAN STANLEY (3.1M shares), STATE STREET CORP (2.92M shares), and Octagon Capital Advisors LP (2.81M shares).
This table shows the top 4 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.